Published in Arch Med Sci on March 04, 2016
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet (2008) 19.58
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 9.05
Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol (1982) 8.47
Partial nephrectomy versus radical nephrectomy in patients with small renal tumors--is there a difference in mortality and cardiovascular outcomes? J Urol (2008) 5.70
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Epidemiology and risk factors for kidney cancer. Nat Rev Urol (2010) 5.25
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dubé syndrome. Cancer Epidemiol Biomarkers Prev (2002) 3.12
Renal oncocytoma: a reappraisal of morphologic features with clinicopathologic findings in 80 cases. Am J Surg Pathol (1997) 3.11
KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol (2005) 2.43
Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation. Radiographics (2006) 2.13
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol (2004) 1.95
Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol (2012) 1.84
Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol (1985) 1.71
A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas. Mod Pathol (2004) 1.61
Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol (2008) 1.60
A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade. Am J Surg Pathol (2010) 1.55
Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies. Oncologist (2012) 1.33
Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene (2003) 1.30
Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev (2009) 1.27
Somatic pairing of chromosome 19 in renal oncocytoma is associated with deregulated EGLN2-mediated [corrected] oxygen-sensing response. PLoS Genet (2008) 1.20
Colloidal iron staining in renal epithelial neoplasms, including chromophobe renal cell carcinoma: emphasis on technique and patterns of staining. Am J Surg Pathol (1998) 1.18
Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. J Exp Clin Cancer Res (2009) 1.07
Renal oncocytoma, yet another tumour that does not fit in the dualistic benign/malignant paradigm? J Clin Pathol (2007) 1.06
Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology (2002) 1.03
Chromophobe cell carcinoma of the kidney. A clinicopathologic study of 21 cases. Am J Surg Pathol (1995) 1.03
Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors. Virchows Arch (2004) 1.02
Chromophobe renal cell carcinoma with extensive calcification and ossification. Ann Diagn Pathol (2002) 0.98
Expression of KIT (CD117) in renal cell carcinoma and renal oncocytoma. Oncology (2005) 0.93
Chromophobe renal cell carcinoma: an immunohistochemical study of 21 Japanese cases. Mod Pathol (1999) 0.92
The chromophobe tumor grading system is the preferred grading scheme for chromophobe renal cell carcinoma. J Urol (2011) 0.90
Valproic acid upregulates NKG2D ligand expression and enhances susceptibility of human renal carcinoma cells to NK cell-mediated cytotoxicity. Arch Med Sci (2013) 0.90
S100A1: a powerful marker to differentiate chromophobe renal cell carcinoma from renal oncocytoma. Histopathology (2007) 0.90
Chromophobe renal cell carcinoma: analysis of 53 cases. J Cancer Res Clin Oncol (2011) 0.86
CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma. BMC Clin Pathol (2009) 0.86
Kinase inhibitors in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol (2006) 0.85
Vimentin reactivity in renal oncocytoma: immunohistochemical study of 234 cases. Arch Pathol Lab Med (2007) 0.84
Clinical implications of pathologic subtypes in renal cell carcinoma. Semin Urol (1990) 0.83
KAI1/CD82 and MRP1/CD9 serve as markers of infiltration, metastasis, and prognosis in laryngeal squamous cell carcinomas. Asian Pac J Cancer Prev (2013) 0.83
Tumour necrosis in chromophobe renal cell carcinoma: clinical data to distinguish aggressive variants. Eur J Surg Oncol (2007) 0.77
Chromosome changes in a metastasis of a chromophobe renal cell tumor. Cancer Genet Cytogenet (1998) 0.76
Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn) (2017) 0.75
Retrospective evaluation of histopathological examinations in invasive ductal breast cancer of no special type: an analysis of 691 patients. Arch Med Sci (2016) 0.75
Expression of multidrug resistance protein P-glycoprotein in correlation with markers of hypoxia (HIF-1α, EPO, EPO-R) in invasive breast cancer with metastasis to lymph nodes. Arch Med Sci (2016) 0.75